Compare Marathon Petroleum Corp (MPC) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marathon Petroleum Corp vs Novavax Inc — how do they compare? Marathon Petroleum Corp trades at $455.51 (market cap $130.12B), while Novavax Inc trades at $12.83 (market cap $1.82B). The key difference: Marathon Petroleum Corp is far larger — about 71.5× Novavax Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marathon Petroleum Corp for 54 Days and Novavax Inc for 59 Days on average.
| MPC | NVAX | |
|---|---|---|
Market Cap | $130.12B | $1.82B |
Volume | 2,749,647 | 6,198,505 |
Sector | Energy | Health |
52-Week High | $463.34 | $12.56 |
52-Week Low | $162.63 | $6.22 |
Typical Hold Time | 54 Days | 59 Days |
Enterprise Value | $156.64B | $1.39B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marathon Petroleum (MPC) trades at $461.79, up 4.42% today, showing strong momentum with three consecutive earnings beats. Technical indicators signal bullish momentum with the stock trading near resistance at $463. Fundamentally, the company maintains solid profitability with 5.57% net margin and 47.9% ROE, though revenue has declined from $177.5B in 2022 to $132.7B in 2025. Analyst consensus remains strongly bullish with 25 buy ratings and a $420.30 price target.
MPC presents a compelling value opportunity with attractive valuation multiples (P/E 16.07, P/S 0.9) and strong earnings momentum. Key risks include potential diesel export restrictions, declining revenue trends, and elevated debt levels. The stock's current price above consensus target suggests near-term caution despite positive technical and fundamental momentum.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
